Shanghai Maiji Biotechnology

Maiji Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on developing innovative antibody therapies for autoimmune and inflammatory diseases. The company utilizes its proprietary antibody discovery and engineering platforms to target validated and emerging pathways in immunology. Its lead asset, MAJ-001, is a monoclonal antibody targeting the IL-4Rα receptor, currently undergoing Phase 2 clinical evaluation for indications such as atopic dermatitis and asthma. Maiji Biotech's pipeline also includes programs targeting TSLP, IL-33, and OX40L, aiming to provide differentiated treatment options for patients with chronic respiratory and skin conditions.